Equities Analysts Offer Predictions for Nicox Q2 Earnings

Nicox SA (OTCMKTS:NICXF) – Equities research analysts at HC Wainwright upped their Q2 2026 earnings estimates for shares of Nicox in a note issued to investors on Wednesday, July 1st. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.01 per share for the quarter, up from their previous forecast of ($0.02). The consensus estimate for Nicox’s current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Nicox’s Q3 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.08) EPS, Q2 2027 earnings at $0.09 EPS, Q3 2027 earnings at ($0.02) EPS and FY2027 earnings at $0.01 EPS.

Nicox Stock Performance

Shares of NICXF stock opened at $0.30 on Friday. Nicox has a one year low of $0.25 and a one year high of $0.30. The firm has a 50-day moving average of $0.30 and a 200-day moving average of $0.30.

About Nicox

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.